Incidence and Mortality Risk Spectrum Across Aggressive Variants of Papillary Thyroid Carcinoma.
暂无分享,去创建一个
M. Luu | G. Braunstein | A. Ho | S. Bose | Z. Zumsteg | W. Sacks | J. Mallen‐St. Clair | Yufei Chen | Nabilah Ali | Chrysanta Patio | Xuemo Fan | Irene Chen | M. Melany | L. Barrios | J. Mallen-St Clair
[1] M. Luu,et al. Mortality risk of nonoperative papillary thyroid carcinoma: a corollary for active surveillance. , 2019, Thyroid : official journal of the American Thyroid Association.
[2] T. Yabuta,et al. Prognostic Impact of the Turin Criteria in Poorly Differentiated Thyroid Carcinoma , 2019, World Journal of Surgery.
[3] A. Jemal,et al. Abstract LB-171: Global variation in prostate cancer incidence and mortality rates, 1980-2013 , 2019, Epidemiology.
[4] R. Tuttle,et al. Risk Stratification in Differentiated Thyroid Cancer: From Detection to Final Follow-up. , 2019, The Journal of clinical endocrinology and metabolism.
[5] J. Shah,et al. NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.
[6] Wenlong Wang,et al. Prediction of novel target genes and pathways involved in tall cell variant papillary thyroid carcinoma , 2018, Medicine.
[7] A. Ho,et al. Evolving management considerations in active surveillance for micropapillary thyroid carcinoma , 2018, Current opinion in endocrinology, diabetes, and obesity.
[8] S. Nguyen,et al. A Comparison of the NCDB and SEER Database for Research Involving Head and Neck Cancer , 2018, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.
[9] R. Munden,et al. The epidemiology of lung cancer. , 2018, Translational lung cancer research.
[10] E. Sokol,et al. Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers , 2018, Clinical Cancer Research.
[11] S. Coughlin,et al. Evaluation of Colorectal Cancer Incidence Trends in the United States (2000–2014) , 2018, Journal of clinical medicine.
[12] D. Boffa,et al. Using the National Cancer Database for Outcomes Research: A Review , 2017, JAMA oncology.
[13] E. Cibas,et al. The 2017 Bethesda System for Reporting Thyroid Cytopathology. , 2017, Journal of the American Society of Cytopathology.
[14] Oscar Lin,et al. Natural History and Tumor Volume Kinetics of Papillary Thyroid Cancers During Active Surveillance , 2017, JAMA otolaryngology-- head & neck surgery.
[15] L. Morris,et al. The USPSTF Recommendation on Thyroid Cancer Screening: Don't "Check Your Neck". , 2017, JAMA otolaryngology-- head & neck surgery.
[16] Michael J Barry,et al. Screening for Thyroid Cancer: US Preventive Services Task Force Recommendation Statement , 2017, JAMA.
[17] T. Nakazawa,et al. Prognostic significance of diffuse sclerosing variant papillary thyroid carcinoma: a systematic review and meta-analysis. , 2017, European journal of endocrinology.
[18] R. Vigneri,et al. Outcome of the Diffuse Sclerosing Variant of Papillary Thyroid Cancer: A Meta-Analysis. , 2016, Thyroid : official journal of the American Thyroid Association.
[19] Sun-Mi Park,et al. Diffuse sclerosing variant of papillary thyroid carcinoma: major genetic alterations and prognostic implications , 2016, Histopathology.
[20] R. Tuttle,et al. Dynamic Risk Stratification in Patients with Differentiated Thyroid Cancer Treated Without Radioactive Iodine. , 2016, The Journal of clinical endocrinology and metabolism.
[21] C. Sander,et al. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. , 2016, The Journal of clinical investigation.
[22] I. Ganly,et al. Increasing diagnosis of subclinical thyroid cancers leads to spurious improvements in survival rates , 2015, Cancer.
[23] Steven J. M. Jones,et al. Integrated Genomic Characterization of Papillary Thyroid Carcinoma , 2014, Cell.
[24] J. Bishop,et al. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] RiveraMichael,et al. Prognostic implications of papillary thyroid carcinoma with tall-cell features. , 2014 .
[26] Louise Davies,et al. Current thyroid cancer trends in the United States. , 2014, JAMA otolaryngology-- head & neck surgery.
[27] S. Roman,et al. Aggressive variants of papillary thyroid microcarcinoma are associated with extrathyroidal spread and lymph-node metastases: a population-level analysis. , 2013, Thyroid : official journal of the American Thyroid Association.
[28] F. Frasca,et al. The tall cell variant of papillary thyroid carcinoma: Clinical and pathological features and outcomes , 2012, Journal of Endocrinological Investigation.
[29] R. Owen,et al. Aggressive variants of papillary thyroid carcinoma , 2011, Head & neck.
[30] R. Vigneri,et al. A diffuse sclerosing variant of papillary thyroid carcinoma: clinical and pathologic features and outcomes of 34 consecutive cases. , 2011, Thyroid : official journal of the American Thyroid Association.
[31] William N. Venables,et al. Modern Applied Statistics with S , 2010 .
[32] I. Ganly,et al. Tall-cell variant of papillary thyroid carcinoma: a matched-pair analysis of survival. , 2010, Thyroid : official journal of the American Thyroid Association.
[33] S. Mandel,et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. , 2009, Thyroid : official journal of the American Thyroid Association.
[34] M. Rivera,et al. Tall cell variant of papillary thyroid carcinoma without extrathyroid extension: biologic behavior and clinical implications. , 2007, Thyroid : official journal of the American Thyroid Association.
[35] S. Bardet,et al. Prevalence and prognostic significance of tall cell variant of papillary thyroid carcinoma. , 2007, Human pathology.
[36] Ram C Tiwari,et al. Efficient interval estimation for age-adjusted cancer rates , 2006, Statistical methods in medical research.
[37] A. Lam,et al. Diffuse Sclerosing Variant of Papillary Carcinoma of the Thyroid: A 35-Year Comparative Study at a Single Institution , 2006, Annals of surgical oncology.
[38] M. Sywak,et al. A review of thyroid cancer with intermediate differentiation , 2004, Journal of surgical oncology.
[39] Sascha O. Becker,et al. Estimation of Average Treatment Effects Based on Propensity Scores , 2002 .
[40] E. Feuer,et al. Permutation tests for joinpoint regression with applications to cancer rates. , 2000, Statistics in medicine.
[41] P. Grambsch,et al. Proportional hazards tests and diagnostics based on weighted residuals , 1994 .
[42] D. Rubin,et al. The central role of the propensity score in observational studies for causal effects , 1983 .
[43] A. Ho,et al. Papillary thyroid microcarcinoma: optimal management versus overtreatment. , 2019, Current opinion in oncology.
[44] A. Jemal,et al. Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.